Mr. Okan Güner

Okan GÜNER, who holds a B.Sc. degree in Chemical Engineering from Boğaziçi University and an MBA from Penn State University, started his professional career at Borusan Machinery. He later joined Pfizer Turkey, where he gained significant experience in several fields, including finance and marketing for 15 years. In 2018, he was appointed Cluster Lead Alliance Markets Europe (Austria, Czech Republic, Romania, Slovakia, Switzerland). He then served as General Manager, Turkey and Russia at Pfizer Upjohn Division, driving the two markets’ financial and operational performance. After serving as General Manager at Viatris, the healthcare company born from the merger between Mylan and Pfizer Upjohn Division, he joined Boehringer Ingelheim Turkey in April 2022 as General Manager and Head of Human Pharma. Founded in 1885 with the mission of developing breakthrough therapies for humans and animals to transform their lives, Boehringer Ingelheim is a global family-owned company with more than 53,000 employees serving over 130 markets. As a leading research-driven biopharmaceutical company and one of the top 20 companies in the pharmaceutical industry, Boehringer Ingelheim aims to improve healthcare and quality of life. The company creates value through innovation in areas of high unmet medical need and focuses on developing innovative therapies. Operating in Turkey since 1994 and currently employing nearly 260 people in the country, Boehringer Ingelheim makes its mark with successful activities in Human Pharma and Animal Health.